Ao MF, Franco OE, Park D, Raman D, Williams K, Hayward SW (2007) Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic. Cancer Res 67: 4244–4253.
Buczek ME, Miles AK, Green W, Johnson C, Boocock DJ, Pockley AG, Rees RC, Hulman G, van Schalkwyk G, Parkinson R, Hulman J, Powe DG, Regad T (2016) Cytoplasmic PML promotes TGF-β-associated epithelial-mesenchymal transition and invasion in prostate cancer. Oncogene 35(26): 3465–3475.
Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L, Yang J (2011) Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 19: 372–386.
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487: 239–243.
Hodson R (2015) Small organ, big reach. Nature 528: S118–S119.
Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y, Huang CY, Wu HC, Lin CT (2008) Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol 214: 445–455.
Hussain M, Le Moulec S, Gimmi C, Bruns R, Straub J, Miller K Group P.S (2016) Differential effect on bone lesions of targeting integrins: randomized phase II trial of abituzumab in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 22(13): 3192–3200.
Ikeda T, Kawaguchi H, Kamekura S, Ogata N, Mori Y, Nakamura K, Ikegawa S, Chung UI (2005) Distinct roles of Sox5, Sox6, and Sox9 in different stages of chondrogenic differentiation. J Bone Miner Metab 23: 337–340.
Jadaan DY, Jadaan MM, McCabe JP (2015) Cellular plasticity in prostate cancer bone metastasis. Prostate Cancer 2015: 651580.
Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, Thompson SK, Zollo M, Spano D, Dhawan P, Sliva D, Subbarayan PR, Sarkar M, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Ye L, Helferich WG, Yang X, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Nowsheen S, Pantano F, Santini D (2015) Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol 35(Suppl): S244–S275.
Kalluri R, Weinberg RA (2009) The basics of epithelial–mesenchymal transition. J Clin Invest 119: 1420–1428.
Lefebvre V, Behringer RR, de Crombrugghe B (2001) L-Sox5, Sox6 and Sox9 control essential steps of the chondrocyte differentiation pathway. Osteoarthritis Cartilage 9(Suppl A): S69–S75.
Lefebvre V, Dumitriu B, Penzo-Mendez A, Han Y, Pallavi B (2007) Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. Int J Biochem Cell Biol 39: 2195–2214.
Liu CF, Lefebvre V (2015) The transcription factors SOX9 and SOX5/SOX6 cooperate genome-wide through super-enhancers to drive chondrogenesis. Nucleic Acids Res 43: 8183–8203.
Ma S, Chan YP, Woolcock B, Hu L, Wong KY, Ling MT, Bainbridge T, Webber D, Chan TH, Guan XY, Lam W, Vielkind J, Chan KW (2009) DNA fingerprinting tags novel altered chromosomal regions and identifies the involvement of SOX5 in the progression of prostate cancer. Int J Cancer 124: 2323–2332.
Massague J (2008) TGF-β in cancer. Cell 134: 215–230.
Mata-Rocha M, Hernandez-Sanchez J, Guarneros G, de la Chesnaye E, Sanchez-Tusie AA, Trevino CL, Felix R, Oviedo N (2014) The transcription factors Sox5 and Sox9 regulate Catsper1 gene expression. FEBS Lett 588: 3352–3360.
Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, de Gramont A (2015) Targeting the TGF-β pathway for cancer therapy. Pharmacol Therapeut 147: 22–31.
Pei XH, Lv XQ, Li HX (2014) Sox5 induces epithelial to mesenchymal transition by transactivation of Twist1. Biochem Biophys Res Commun 446: 322–327.
Pickup M, Novitskiy S, Moses HL (2013) The roles of TGF-β in the tumour microenvironment. Nat Rev Cancer 13: 788–799.
Renjie W, Haiqian L (2015) MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. Cancer Lett 356: 568–578.
Sekiya I, Vuoristo JT, Larson BL, Prockop DJ (2002) In vitro cartilage formation by human adult stem cells from bone marrow stroma defines the sequence of cellular and molecular events during chondrogenesis. Proc Natl Acad Sci USA 99: 4397–4402.
Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1): 7–30.
Steinberger AE, Ledet EM, Luk E, Cotogno P, Stolten M, Desmond D, Feibus A, Silberstein J, Sartor O (2016) Characterizations of clinical and therapeutic histories for men with prostate cancer-specific mortality. Clin Genitourin Cancer 14: 139–148.
Ten Dijke P, Arthur HM (2007) Extracellular control of TGF-beta signalling in vascular development and disease. Nat Rev Mol Cell Biol 8: 857–869.
Thakur N, Gudey SK, Marcusson A, Fu JY, Bergh A, Heldin CH, Landstrom M (2014) TGF-β-induced invasion of prostate cancer cells is promoted by c-Jun-dependent transcriptional activation of Snail1. Cell Cycle 13: 2400–2414.
Thiery JP, Lim CT (2013) Tumor dissemination: an EMT affair. Cancer Cell 23: 272–273.
Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A (2006) Transforming growth factor-beta employs HMGA2 to elicit epithelial–mesenchymal transition. J Cell Biol 174: 175–183.
Tsai JH, Yang J (2013) Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 27: 2192–2206.
Wang D, Han S, Wang X, Peng R, Li X (2015) SOX5 promotes epithelial–mesenchymal transition and cell invasion via regulation of Twist1 in hepatocellular carcinoma. Med Oncol 32: 461.
Wu KK (2006) Analysis of protein-DNA binding by streptavidin-agarose pulldown. Methods Mol Biol 338: 281–290.
Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L, Fazli L, Gleave ME, Wang Y, Rennie P, Dong X (2015) The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer 136: E27–E38.